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tumors especially lung cancer which impact outcome. Post-treatment 
surveillance is therefore practiced on the premise that early detection 
and timely treatment of recurrences and second primary lung cancers 
(SPLC) could improve outcome. 
Objectives: To determine the outcome of curatively treated HNC 
patients referred because of the suspicion of SPLC. 
Methods: Between 1996 and 2005, patients with HNC referred for 
respiratory symptoms and/ or radiological abnormalities suspicious for 
lung cancer were evaluated with radiology and autoﬂuorescence bron-
choscopy. Data on patient demographics, smoking, pack years, cancer 
characteristics and outcome were collected and analyzed.
Results: Fifty-one patients (44 males) with curatively treated N0 
HNC were evaluated. Median age was 70 years (range, 63-79), all 
were current or former smokers of 35 pack years (range, 30-45) and 
25 had chronic obstructive lung disease. With a median follow up of 
60 months, 8 patients were diagnosed with synchronous and 26 with 
metachronous SPLC. A total of 42 SPLC were diagnosed; 12 (29%) in 
the central airways and 30 (71%) parenchymal. Median time to meta-
chronous SPLC was 24 months. Most of SPLC (38/42) were surgically 
resectable. Five occult cancers detected by AF bronchoscopy were 
successfully treated with endobronchial therapy. Lung cancer mortal-
ity was 24%. Survival of synchronous and metachronous SPLCs was 
signiﬁcantly shorter (83 and 144 months) compared to those with HNC 
alone (240 months) (p=0.002).
Conclusion: SPLC has a negative impact on the survival of patients 
with HNC. Close surveillance with autoﬂuorescence bronchoscopy and 
CT for SPLC combined with aggressive treatment of early stage lung 
cancer might be a strategy to improve outcome. 
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Background: Harbor Hospital is located in downtown Baltimore, 
serving largely blue-collar workers with very high smoking prevalence. 
Non-small cell lung cancer is the most common malignancy seen at 
this hospital, usually diagnosed at inoperable or metastatic stages. We 
pioneered low-cost and free chest CT scan program for this high risk 
population based on recent data indicating that yearly screening CT 
scans of chest can lead to early lung cancer diagnosis, and may reduce 
the lung cancer mortality.
Methods: Low cost screening chest CT scan was advertised through 
mass media and was offered to general population. We secured outside 
funding for approximately 300 free screening chest CT scans and these 
were offered through local primary care providers who were asked to 
identify individuals at high risk for lung cancer development based 
on their smoking and/or asbestos exposure history. Overall eligibility 
criteria for screening CT scan were age 55 and above, with at least 20 
pack-year smoking history. All CT scans were done at Harbor Hospital 
Radiology Department, and results were classiﬁed as negative, indeter-
minate or suspicious. Indeterminate or suspicious results were reviewed 
and discussed at the multidisciplinary Lung Tumor conference and 
follow-up recommendation was issued according to the Early Lung 
Cancer Action Program (ELCAP) guidelines.
Results: A total of 492 patients underwent screening chest CT scans 
between 3/2003 and 2/2006. Median age of patients was 57 years 
(33-80), with 261(53%) women and 231(47%) men. The majority of 
screened population was Caucasian (68%), with 20% African Ameri-
cans and small number of Asians (3%). More than 95% of the patients 
were current or ex-smokers, with median of 33-pack year smoking 
history (3-200). Among 459 smokers, 133 (29%) were former smokers 
with median of 10-year smoking cessation history (1mo to 40 years). 
Initial CT scan results were reported as normal in 258 (52%) and 
indeterminate in 234(48%). Non-small cell lung cancer was diagnosed 
in 8 patients (1.6%), who were referred to appropriate disciplines for 
staging and treatment. Three out of 8 patients were found to have stage 
I/II NSCLC and underwent surgical resection. Total of 10 out of 492 
patients were diagnosed with cancer, two additional patients were inci-
dentally found with other types of cancers, one laryngeal and another 
with pancreatic cancer. 
Conclusion: Eight cases of NSCLC were diagnosed after screen-
ing 492 high-risk populations at a community hospital in downtown 
Baltimore. Among them, three patients (38%) were found to have early 
stage lung cancer and were offered curative resection. Following our 
experience, many other local community hospitals engaged in similar 
programs to provide low cost chest CT scans for early lung cancer 
detection. In our limited experience, screening chest CT scans yielded 
relatively more early stage lung cancers than our historical control. 
The usefulness of this approach remains to be established with ongo-
ing large multicenter randomized trials sponsored by National Cancer 
Institute and ELCAP. 
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Background: Bronchial epithelial proliferation as measured by Ki-67 
immunostaining is a biologically plausible intermediate endpoint 
biomarker of lung cancer risk, but has not been validated. We designed 
a study to determine factors associated with increased bronchial epi-
thelial proliferation and whether increased epithelial proliferation is as-
sociated with endobronchial dysplasia, chronic obstructive pulmonary 
disease or lung cancer.
Methods: Cross-sectional study of 113 subjects undergoing white light 
and autoﬂuorescence bronchoscopy; 27 never smokers, 27 current or 
ex-smokers with normal spirometry, 31 current or ex-smokers with 
COPD and 28 current, ex- or never smokers with lung cancer. Ki-67 
expresssion was determined by immunohistochemistry on all evaluable 
biopsy sites without carcinoma. A Ki-67 index was deﬁned as the per-
cent of cells expressing Ki-67. Relationships between Ki-67 index and 
demographic variables, smoking, histology and the presence of COPD 
and/or lung cancer were determined.
Results: Results for both maximal and mean Ki-67 index are similar, 
so only the former are reported. Average maximal Ki-67 index was 
higher in current smokers than either ex-smokers or never smok-
ers (48.0% vs 30.6% vs 22.6%; p<0.001). Males had higher Ki-67 
index than females, (39.9% vs 23.6% p<0.001). Compared to subjects 
without disease (Ki67 index = 30.0%) maximal Ki-67 index was not 
signiﬁcantly elevated (p = 0.44) in subjects with either lung cancer 
(Ki67 = 39.1%) or COPD (Ki67 = 38.9%) 
Conclusions: Current smoking and gender are major determinants of 
Ki-67 index. No increase in Ki-67 index was found in the non-malig-
nant epithelium of patients with lung cancer or COPD. Although Ki-67 
index may provide insight into the short-term effects of chemopreven-
tion agents on cell proliferation, its lack of association with lung cancer 
or COPD raise question about its utility as a surrogate endpoint in 
clinical trials. 
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Background: Chemically induced murine adenocarcinomas contain 
many of the same histological and genetic alterations found in human 
adenocarcinomas, afﬁrming the importance of murine tumorigenesis 
models. Increased pulmonary PGI2 (prostacyclin) by lung-speciﬁc 
overexpression of prostacyclin synthase (PGIS) chemoprevents lung 
cancer in chemically induced and cigarette smoke exposure models, 
suggesting that PGI2 plays a role in the development of NSCLC. Al-
terations in EGFR by mutation or increased copy number are identiﬁed 
in a subset of lung cancers, and targeted therapies with tyrosine kinase 
inhibitors (TKIs) are currently in clinical use for NSCLC. We hypothe-
sized that the TKI geﬁtinib would provide synergistic chemoprevention 
of murine lung cancer when combined with PGIS overexpression. 
Methods: PGIS overexpressors and their wild-type littermates were 
given a single intraparitoneal (i.p.) injection of urethane. After one 
week, body-weight based i.p. injections of geﬁtinib were given in doses 
of 50mg/kg (n=45), 100mg/kg (n=41) or vehicle alone (tween 80R, 
n=43) three times per week. Serial body weights were followed during 
the experiment, and at the time of sacriﬁce (18 weeks after urethane) 
lung tissue and tumors were collected. Lung tissue was snap frozen, 
stored in formalin or RNA later, or immediately used for analysis of 
PGE2 and 6-keto PGF1α (the stable metabolite of PGI2) eicosanoid 
levels. Additional overexpressing and wild-type animals (n=12 in each 
group) received geﬁtinib for two weeks only, after which lung tissue 
was harvested for studies to determine if EGFR inhibition was success-
ful. Western blots for p-Erk, p-Src, and p-Akt were performed on lung 
homogenates from all treatment groups.
Results: PGIS overexpressors, when compared with transgene negative 
littermates, showed signiﬁcant decreases in tumor multiplicity consis-
tent with our prior studies. A further reduction in tumor multiplicity 
(1.13 ± 0.29 vs. 2.29 ± 0.32 tumors/mouse, p=0.0149) was observed in 
the 50mg/kg treatment group versus the vehicle alone. No additional 
effects were realized in the 100mg/kg treatment group (2.00 ± 0.32 
tumors/mouse, p=0.5340). No signiﬁcant differences in tumor burden 
or eicosanoid levels were observed among the experimental groups. 
Analysis of p-Erk, p-Src, and p-Akt in PGIS treated animals showed 
decreases in the 50mg/kg treatment group, while the 100mg/kg group 
showed a paradoxical return of p-Src. Western blot analyses of p-Ten 
and cleaved caspase 3 continue to be performed.
Conclusions: Animals tolerated i.p. injection at doses of 50mg/kg and 
100mg/kg. Lung homogenates from geﬁtinib-treated mice showed a de-
crease in p-EGFR following EGF exposure, demonstrating successful 
inhibition of EGFR in our model. At a dose of 50mg/kg, treatment with 
geﬁtinib was synergistic with PGIS overexpression in decreasing tumor 
multiplicity. The observed increases in p-Src in both wild-type and 
PGIS mice in the 100mg/kg treatment group suggest a mechanism of 
adaptation to EGFR inhibition. Future investigations into the synergy 
of prostacyclin manipulation and EGFR inhibition are planned. 
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Objectives: EDIFICE study was aimed at improving knowledge of 
the French population adherence to screening tests for the four most 
frequent cancers: breast, colon-rectum, prostate and lung cancers. The 
results pertaining to lung cancer are summarised below. 
Methods: This was an observational survey conducted in France 
among a representative sample of 1 504 subjects aged 40 to 75 years 
without history of cancer and among a representative sample of 600 
general practitioners (GPs). 
Results: Individual screening for lung cancer using chest radiography 
had been performed by 6% of subjects (of whom 51% were women). 
Compared with the unscreened subjects, more screened subjects were 
smokers (33% versus 23%; p<0.05). Cancer screening had often been 
initiated by the GP (22%) or the company doctor (21%). Regarding the 
screened subjects’ proﬁle, mean age was 54.5 years; their socio-profes-
